State-of-the-Art Review: Pharmacology and Pharmacokinetics of Antithrombotic Agents

Vermylen J. , Verstraete M. , Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 1986;8:2B.

Zucker MB , Nachmias VT Platelet activation. Arteriosclerosis 1985;5:2.

Unkeless J. , Dano K. , Kellerman G. , et al. Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of cell factors, a plasminogen activator . J Biol Chem 1974; 249:4295.

Schoefield FW A brief account of a disease of cattle simulating hemorrhagic septicaemia due to feeding sweet clover. Can Vet Rec 1922;3:74.

Jackson CM , Suttie JW , Recent developments in understanding the mechanism of vitamin K and vitamin K-antagonist drug action and the consequences of vitamin K in blood coagulation . Prog Haematol 1977;10:333-9.

Bell RG , Matschiner RJ Warfarin and the inhibition of vitamin K activity by an epoxide metabolite . Nature 1972;237:32-3.

Whitlon DS , Sadowski JA , Suttie JW Mechanism of coumarin action and significance of vitamin K-epoxide reductase inhibition. Biochem 1978;17:1371-7.

O'Reilly RA , Aggler PM Studies on coumarin anticoagulant drugs: Initiation of warfarin therapy without a loading dose. Circalation 1968;38:169-73.

Lewis RJ , Trager WF , Chan KK , et al. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974;53:1607-17.

O'Reilly RA Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974;16:348-54.

Breckenridge AM , Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther 1973;14:955-61.

Bell RG Mechanism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. Fed Proc 1978; 37:2599-604.

Holford Nhg. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11:483-504.

O'Reilly RA , Kowitz PE Studies on the coumarin anticoagulant drugs: Interaction of human plasma albumin and warfarin sodium. J Clin Invest 1967;46:829-37.

O'Rielly RA Interaction of several coumarin compounds with human and canine plasma albumin. Mol Pharmacol 1970;7:209-18.

Yacobi A. , Levy G. Protein binding of warfarin enantiomers in serum of humans and rats. J Pharmacokinet Biopharm 1977;5: 123-31.

Soloman H. , Schrogie J. The effect of various drugs on the binding of warfarin-14C to human albumin . Biochem Pharmacol 1967;16: 1219-26.

Sutcliffe FA , MacNicoll AP , Gibson GG Aspects of anticoagulant action: a review of pharmacology metabolism and toxicology of warfarin and congeners, Drug Metab Drug Int 1987;5:225-72.

Seller EM , Koch-Wesser J. Interaction of warfarin stereoisomers with human albumin. Pharmac Rec Commun 1975;7:331-9.

Testa B. Regio- and stereoselectivity in drug metabolism: two examples. Pharm Int 1981;2:34-7.

Lewis RJ , Trager WF The metabolic fate of warfarin: studies on metabolites in the plasma. Ann NY Acad Sci 1971;179:205-12.

Yacobi A. , et al. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 1976;19:552-8.

Lewis RJ , Trager WF Warfarin metabolism in man: Identification of metabolites in urine. J Clin Invest 1970:49:907-13.

Blanchard RA , Furrie BC , Jorgensen M. , et al. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981;305:242-8.

Ristola P. , Kaleui P. Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction. Acta Med Scand 1972 ; 192:183-8.

Ganeval D. , Fischer AM , Barre J. , et al. Pharmacokinetics of warfarin in nephrotic syndrome and effect on vitamin k-dependent clotting factors. Clin Nephrol 1986;25:75-80.

Nader HB , Takahashi HK , Straus AH , Dietrich CP Selective distribution of heparin in mammals: conspicuous presence of heparin in lymphoid tissues. Biochim Biophys Acta 1980;627:40-48.

Straus AH , Nader HB , Dietrich CP Absence of heparin or heparin-like compounds in mast.cell-free tissues and animals. Biochim Biophys Acta 1982;717:478-85.

Rosenberg RD , Damus PS The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248:6490-505.

Griffith MJ Kinetics of the heparin-enhanced antithrombin III/ thrombin reaction: evidence for a template model for the mechanism of action of heparin. J Biol Chem 1982;257:7360-5.

Pomerantz MW , Owen WG A catalytic role for heparin: evidence for a ternary complex of heparin cofactor thrombin and heparin. Biochim Biophys Acta 1978;535:66-77.

Carlstrom AS , Lieden K. , Bjork I. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. Thromb Res 1977;11:785-97.

Larsen AK , Lund DP , Langer R. , Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Nat Acad Sci USA 1986;83:2964-8.

Emanuele RM , Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987:48:591-6.

Briant L. , Caranobe C. , Saivin S. , et al. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989;61:348-53.

Kandrotas. RJ , Gal P. , Douglas JB. Deterding J. Heparin pharmacokinetics during hemodialysis. Ther Drug Monit 1989; 11:674-9.

Kandrotas RJ , Gal P. , Douglas JB , Deterding J. Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability. Pharmacotherapy 1990;10:349-56.

van Rijn Jlml , Trilliou M. , Mardiguian J. , Tobelem G. , Caen J. Selective binding of heparins to human endothelial cells: implications for pharmacokinetics. Thromb Res 1988;49:373-83.

Vannucci S. , Pasquali F. , Porciatti F. , et al. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells. Thromb Res 1988;49:373-83.

Hiebert LM , McDuffie NM The intracellular uptake and protracted release of exogenous heparins by cultured endothelial cells. Arzery 1989;16:208-22.

Mastacchi R. , Barbanti M. Inactivation of the heparin anticoagulant activity by rat kidney lysosomal enzymes. Thromb Res 1987;47: 101-6.

Proctor RR , Rapaport SI The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961:36:212-9.

Basu D. , Gallus A. , Hirsh J. , Cade J. A prospective study of the value of monitoring heparin treatment with the activated thromboplastin time. N Engl J Med 1972;287:324-7.

Hull RD , Raskob GE , Hirsh J. , et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315: 1109-14.

Holm HA , Abildgaard U. , Kalvenes S. , et al. The antithrombotic effect of heparin in deep vein thrombosis: relation to four heparin assays. Acta Med Scand 1984;216:287-93.

van Putten J. , van de Ruit M. , Beunis M. , Hemker HC Interindividual variation in relationships between plasma heparin concentration and the result of five heparin assays . Clin Chim Acta 1982; 122:261-70.

Teien AN , Lie M. Evaluation of an amidolydic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977:10:399-410.

Kandrotas RJ , Gal P. , Douglas JB , Groce JB Rapid determination of maintenance heparin infusion rates with the use of non-steady-state heparin concentrations. Ann Pharmacother 1993;27:1429-33.

Tien AN , Bjornsson J. Heparin elimination in uremic patients on haemo-dialysis. Scand J Haematol 1976; 17:29-35.

Perry PJ , Herron GR , King JC Heparin half-life in normal and impaired renal function. Clin Pharmacol Ther 1974;16:514-9.

Hirsh J. , van Aken WG , Gallas AS , et al. Heparin kinetics in venous thrombosis and pulmonary embolism . Circulation 1976; 53:691-5.

Simon TL , Hyers TM , Gaston JP , Harker LA Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978:11:111-20.

Cipolle RJ , Seifert RD , Neilan BA , Zaske DE , Haus H. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-93.

Kandrotas RJ , Gal P. , Douglas JB , Groce JB , Hansen CJ Altered heparin pharmacodynamics in patients with pulmonary embolism. Ther Drug Monit 1992 ;14:360-5.

Fareed J. , Walenga JM , Hoppensteadt D. , Huan X. , Nonn R. Biochemical and pharmacologic inequivalance of low molecular weight heparins . Ann NY Acad of Sci 1989;556:333-53.

Nielsen JI , Ostergaard P. Chemistry of heparin and low molecular weight heparins. Acta Chir Scand 1988;543:52-6,

Solandt DY , Best CH Time relations of heparin action on blood clotting and platelet agglutination . Lancet 1940;233:1042-4.

Ofosu F. , Blajchman MA , Hirsh J. The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. Thromb Res 1980:20:391-403.

Ofosu FA , Modi G. , Cerskus AL , Hirsh J. , Blajchman MA Heparin with low affinity to antithrombin-III inhibits the activation of prothrombin in normal plasma. Thromb Res 1982;28:487-97.

Carter CJ , Kelton JG , Hirsh J. , et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982;59:1239-45.

Chiu HM , Hirsh J. , Yung WL , Regoeczi E. Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977 ;49:171-84.

Ockelford PA , Carter CJ , Mitchell L. , Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction . Thromb Res 1982;28: 401-9.

Bergqvist D. , Nilsson B. , Hedner U. , Pedersen PC , Ostergaard PB The effects of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985;38: 589-601.

Buchanan MR , Boneu B. , Ofosu F. , Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985;65:198-201.

Fareed J. , Jeske W. , Hoppensteadt D. , Clarizio R. , Walenga JM Are the available low-molecular-weight heparin preparations the same? Semin Thrombos Hemostas 1996:22:77-90.

Bara L. , Billaud E. , Kher A. , Samama M. Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin. Semin Thromb Hemost 1985; 11:316-7.

Emanuele RM , Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987;48:591-6.

Kandrotas RJ Heparin pharmacokinetics and pharmacodynamics , Clin Pharmacokinet 1992;22:359-74.

Frydman M. , Bara L. , Le Roux Y. , et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin in humans given a single subcutaneous dose of 20-80 mg. J Clin Pharmacol 1988;28:609-18.

Boneu B. , Buchanan MR , Caranobe C. , et al. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard in rabbits. Thromb Res 1987;46:845-53.

Palm M. , Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987;58:932-5.

Palm M. , Mattsson C. Pharmacokinetics of Fragmin: a comparative study in the rabbit of its high and low affinity forms for antithrombin. Thromb Res 1987;48:51-62.

Bara L. , Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988;543:65-72.

Dawes J. , Bara L. , Billaud E. , Samama M. Relationship between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration, Haemostasis 1986 ;16:116-22.

Follea G. , Laville M. , Pozet N. , Dechavanne M. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 1986;16:147-51.

Goudable C. , That HT , Damani A. , et al. Low molecular weight heparin half-life is prolonged in haemodialysis patients. Thromb Res 1986;43:1-5.

Marbet GA , Verstraete M. , Kienast J. , et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39 393) in healthy volunteers. J Cardiovavc Pharmacol 1993;22: 364-72.

Fox I. , Dawson A. , Loynds P. , et al. Anticoagulant activity of Hirulog™ a direct thrombin inhibitor in humans. Thromb Haemost 1993;69:157-63.

Stringer KA , Lindenfield J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992;26:1535-40.

Markwardt F. , Nowak G. , Sturzebecher J. , Walsman P. Studies on the pharmacokinetics of hirudin . Biomed Biochim Acta 1987;46: 237-44.

Markwardt F. , Nowak G. , Sturzebecher J. , Griesbach U. , Walsmann P. , Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984;52:160-3.

Chardot JA , Lefevre GY , Godbillon JA Pharmacokinetics of rechirudin in healthy volunteers after intravenous administration . J Pharmacokin Biopharm 1994:22:147-56.

Bilcher J. , Siebeck M. , Fichtl B. , Fritz H. Pharmacokinetic effect on clotting tests and assessment of immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man. Haemostasis 1991;21 (suppl 1):137-41.

Nowak G. Pharmacokinetics of hirudin. Semin Thromb Hemost 1991;17:145-9.

Schiele F. , Vuillemenot A. , Kramarz P. , et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20-5.

van den Bos AA , Deckers JW , Heyndrickx GR , et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993;88:2058-66.

Nowak G. , Bucha E. , Gook TH , Thieler H. , Markwardt F. Pharmacology of r-Hirudin in renal impairment. Thromb Res 1992;66: 707-15.